Breaking News, Financial News

Financial Report: Biogen Idec 1Q11

Growth in the quarter was primarily driven by Tysabri revenues, up 15% to $251 million, and Avonex sales, up 8% to $642 million.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec 1Q11 1Q Revenues: $1.2 billion (+9%) 1Q Earnings: $308.8 million (+40%) Comments: Growth in the quarter was primarily driven by Tysabri revenues, up 15% to $251 million, and Avonex sales, up 8% to $642 million. Rituxan revenues from the company’s joint business arrangement with Elan were flat at $256 million for the quarter. Other product revenue in the quarter was flat at $13 million....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters